OCUGEN, INC. (OCGN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.39M; Additional Paid in CapitalUSD $432.01M; Treasury Stock, Common, ValueUSD $48.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.38M; Additional Paid in CapitalUSD $429.55M; Treasury Stock, Common, ValueUSD $48.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.12M; Additional Paid in CapitalUSD $392.76M; Treasury Stock, Common, ValueUSD $48.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $3.12M; Additional Paid in CapitalUSD $390.76M; Treasury Stock, Common, ValueUSD $48.00K.
OCUGEN, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Outstanding USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value USD | Treasury Stock, Value, Acquired, Cost Method USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $3.39M | $432.01M | $48.00K | $213.00K | $-452.12M | $-16.56M | (m) | 121.50K | 3 month · $1.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $3.38M | $429.55M | $48.00K | $164.00K | $-427.24M | $5.80M | (m) | 121.50K | 3 month · $2.06M | 1 month · $14.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $3.12M | $392.76M | $48.00K | $61.00K | $-408.07M | $-12.17M | (m) | 121.50K | 12 month · $7.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $3.12M | $390.76M | $48.00K | $58.00K | $-390.36M | $3.53M | (m) | 121.50K | 3 month · $1.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.92M | $370.47M | $48.00K | $12.00K | $-370.31M | $3.05M | (m) | 121.50K | 3 month · $1.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $2.92M | $368.57M | $48.00K | $40.00K | $-355.57M | $15.91M | (m) | 121.50K | 3 month · $1.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $2.92M | $366.94M | $48.00K | $48.00K | $-340.22M | $29.63M | (m) | 121.50K | 12 month · $7.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $2.90M | $364.09M | $48.00K | $23.00K | $-326.34M | $40.63M | (m) | 121.50K | 3 month · $1.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $2.58M | $327.74M | $48.00K | $28.00K | $-313.37M | $16.93M | (m) | 121.50K | 3 month · $1.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.58M | $325.80M | $48.00K | $25.00K | $-298.09M | $30.26M | (m) | 121.50K | 3 month · $1.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.00K | $2.57M | $324.19M | $48.00K | $20.00K | $-286.17M | $40.56M | $4.10M | 121.50K | 12 month · $9.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.57M | $322.45M | $48.00K | $27.00K | $-275.20M | $49.80M | (m) | 121.50K | 3 month · $2.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.57M | $320.18M | $48.00K | $22.00K | $-263.48M | $59.24M | (m) | 121.50K | 3 month · $2.63M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.27M | $303.07M | $48.00K | $25.00K | $-240.41M | $64.90M | (m) | 121.50K | 3 month · $2.69M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $2.22M | $294.87M | $48.00K | $26.00K | $-223.09M | $73.98M | $4.10M | 121.50K | 12 month · $10.54M | (m) | (m) | $48.00K | (m) | 12 month · $200.00K | (m) | (m) |
| 2022-09-30 | (m) | $2.17M | $284.23M | $48.00K | $30.00K | $-200.69M | $85.69M | (m) | 121.50K | 3 month · $2.50M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.16M | $281.14M | $48.00K | $10.00K | $-176.78M | $106.48M | (m) | 121.50K | 3 month · $2.08M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.16M | $278.70M | $48.00K | $0.00 | $-155.30M | $125.52M | (m) | 121.50K | 3 month · $3.30M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2021-12-31 | $5.00M | $2.00M | $225.54M | (m) | $0.00 | $-131.67M | $91.20M | (m) | 121.50K | 12 month · $6.96M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.99M | $222.25M | (m) | (m) | $-117.09M | $107.11M | (m) | 121.50K | 3 month · $1.35M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.99M | $220.80M | (m) | (m) | $-106.33M | $116.41M | (m) | 121.50K | 3 month · $2.10M | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.88M | $125.03M | (m) | (m) | $-80.38M | $46.49M | (m) | 121.50K | 3 month · $833.00K | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $1.84M | $93.06M | (m) | (m) | $-73.30M | $21.55M | (m) | 121.50K | 12 month · $660.00K | (m) | (m) | $48.00K | (m) | (m) | (m) | (m) |
| 2020-09-30 | $0.00 | $1.62M | $82.36M | (m) | (m) | $-69.51M | $14.42M | (m) | 121.50K | 3 month · $126.00K | (m) | (m) | $47.86K | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $1.35M | $72.36M | (m) | (m) | $-59.04M | $14.62M | (m) | 121.50K | 3 month · $149.00K | (m) | (m) | $47.86K | (m) | 3 month · $700.00K | (m) | (m) |
| 2020-03-31 | $0.00 | $527.47K | $62.24M | (m) | (m) | $-55.42M | $7.30M | (m) | 121.50K | 3 month · $222.00K | (m) | (m) | $47.86K | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $527.47K | $62.02M | (m) | (m) | $-51.48M | $11.02M | (m) | 121.50K | 12 month · $884.00K | (m) | (m) | $47.86K | 12 month · $48.00K | (m) | (m) | (m) |
| 2019-09-30 | (m) | $100.14K | $50.67M | (m) | (m) | $-63.86M | $-13.09M | (m) | (m) | 3 month · $193.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $13.02K | $34.97M | (m) | (m) | $-41.09M | $-6.11M | (m) | (m) | 3 month · $111.81K | (m) | $219.91M | (m) | (m) | (m) | (m) | (m) |
| 2019-05-16 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2019-04-05 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.00M | (m) |
| 2019-03-31 | (m) | $839.00K | (m) | (m) | (m) | $-226.25M | $-18.61M | (m) | (m) | 3 month · $415.20K | (m) | $219.87M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $49.61K | $18.48M | (m) | $451.00 | $31.24M | $-12.71M | (m) | 0.00 | 12 month · $1.07M | (m) | $215.86M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $221.00K | (m) | (m) | (m) | $-216.01M | $-7.08M | (m) | (m) | 3 month · $226.22K | (m) | $206.12M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $186.00K | (m) | (m) | (m) | $-226.80M | $-5.37M | (m) | (m) | 3 month · $261.19K | (m) | $203.17M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $186.00K | (m) | (m) | (m) | $-223.02M | $-345.39K | (m) | (m) | 3 month · $258.68K | (m) | $202.76M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $159.00K | (m) | (m) | (m) | $-208.19M | $4.43M | (m) | (m) | 12 month · $1.57M | (m) | $196.76M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $159.00K | (m) | (m) | (m) | $-201.39M | $-4.81M | (m) | (m) | (m) | (m) | $196.42M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $159.00K | (m) | (m) | $-2.00K | $-195.40M | $806.00K | (m) | (m) | (m) | (m) | $196.04M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $159.00K | (m) | (m) | $-6.00K | $-188.85M | $6.97M | (m) | (m) | (m) | (m) | $195.67M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $159.00K | (m) | (m) | (m) | $-181.77M | $13.57M | (m) | (m) | 12 month · $1.55M | (m) | $195.18M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $159.00K | (m) | (m) | (m) | $-190.84M | $4.04M | (m) | (m) | (m) | (m) | $194.71M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $133.00K | (m) | (m) | (m) | $-181.52M | $12.89M | (m) | (m) | (m) | (m) | $194.28M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $133.00K | (m) | (m) | (m) | $-173.48M | $20.59M | (m) | (m) | (m) | (m) | $193.94M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $132.00K | (m) | (m) | (m) | $-165.56M | $28.20M | (m) | (m) | 12 month · $1.23M | 12 month · $11.00K | $193.63M | (m) | (m) | 12 month · $377.00K | (m) | (m) |
| 2015-09-30 | (m) | $132.00K | (m) | (m) | (m) | $-157.22M | $36.18M | (m) | (m) | (m) | (m) | $193.26M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $132.00K | (m) | (m) | (m) | $-149.14M | $43.87M | (m) | (m) | (m) | (m) | $192.87M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $132.00K | (m) | (m) | (m) | $-141.50M | $51.22M | (m) | (m) | (m) | (m) | $192.60M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $127.00K | (m) | (m) | (m) | $-133.54M | $54.21M | (m) | (m) | 12 month · $547.00K | 12 month · $51.00K | $187.62M | (m) | (m) | 12 month · $8.46M | (m) | 12 month · $3.52M |
| 2014-12-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.90M | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $-75.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |